MDXH Fundamental Analysis - MDxHealth SA

Name: MDxHealth SA (MDXH) Stock
Brand: MDxHealth SA
Rating: 6 (3 reviews)

Fundamental Rating

Overall MDXH gets a fundamental rating of 2 out of 10. We evaluated MDXH against 76 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. MDXH is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MDXH has reported negative net income.

MDXH had negative earnings in each of the past 5 years.

In the past 5 years MDXH always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -51.61%, MDXH is doing worse than 63.64% of the companies in the same industry.

The Return On Equity of MDXH (-393.48%) is worse than 75.32% of its industry peers.

		Industry Rank	Sector Rank
ROA	-51.61%
ROE	-393.48%
ROIC	N/A

ROA(3y)-55.15%

ROA(5y)-64.23%

ROE(3y)-343.17%

ROE(5y)-262.12%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 59.66%, MDXH is doing good in the industry, outperforming 64.94% of the companies in the same industry.

MDXH's Gross Margin has declined in the last couple of years.

MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	59.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-6.79%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MDXH has been increased compared to 1 year ago.

Compared to 1 year ago, MDXH has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.

MDXH's Altman-Z score of -3.05 is on the low side compared to the rest of the industry. MDXH is outperformed by 71.43% of its industry peers.

A Debt/Equity ratio of 2.17 is on the high side and indicates that MDXH has dependencies on debt financing.

The Debt to Equity ratio of MDXH (2.17) is worse than 75.32% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.17
Debt/FCF	N/A
Altman-Z	-3.05

ROIC/WACCN/A

WACC6.93%

2.3 Liquidity

MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of MDXH (2.43) is comparable to the rest of the industry.

A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.

With a Quick ratio value of 2.27, MDXH perfoms like the industry average, outperforming 44.16% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.43
Quick Ratio	2.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MDXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.81%.

The Revenue has grown by 66.59% in the past year. This is a very strong growth!

The Revenue has been decreasing by -1.77% on average over the past years.

EPS 1Y (TTM)-16.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-700%

Revenue 1Y (TTM)66.59%

Revenue growth 3Y46.47%

Revenue growth 5Y-1.77%

Sales Q2Q%73.48%

3.2 Future

Based on estimates for the next years, MDXH will show a very strong growth in Earnings Per Share. The EPS will grow by 51.91% on average per year.

Based on estimates for the next years, MDXH will show a very strong growth in Revenue. The Revenue will grow by 27.69% on average per year.

EPS Next Y-6519.8%

EPS Next 2Y-619.83%

EPS Next 3Y-49.87%

EPS Next 5Y51.91%

Revenue Next Year84.81%

Revenue Next 2Y47.5%

Revenue Next 3Y43.11%

Revenue Next 5Y27.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.

Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-619.83%

EPS Next 3Y-49.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDXH!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap82.41M

Revenue(TTM)89.55M

Net Income(TTM)-70039000

Analysts86.67

Price Target8.4 (178.15%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)86.3%

Min EPS beat(2)82.17%

Max EPS beat(2)90.44%

EPS beat(4)4

Avg EPS beat(4)88.67%

Min EPS beat(4)82.17%

Max EPS beat(4)98.56%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)64.31%

Min Revenue beat(2)6.24%

Max Revenue beat(2)122.37%

Revenue beat(4)4

Avg Revenue beat(4)65.41%

Min Revenue beat(4)6.24%

Max Revenue beat(4)122.37%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)814.71%

PT rev (3m)814.71%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-889.37%

EPS NY rev (3m)-731.51%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-0.5%

Revenue NY rev (3m)1.18%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.01
P/FCF	N/A
P/OCF	N/A
P/B	5.1
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.68

EYN/A

EPS(NY)-4.7

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS2.98

BVpS0.59

TBVpS-2.08

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-51.61%
ROE	-393.48%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	59.66%
FCFM	N/A

ROA(3y)-55.15%

ROA(5y)-64.23%

ROE(3y)-343.17%

ROE(5y)-262.12%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-6.79%

F-ScoreN/A

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	2.17
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.43
Quick Ratio	2.27
Altman-Z	-3.05

F-ScoreN/A

WACC6.93%

ROIC/WACCN/A

Cap/Depr(3y)43.52%

Cap/Depr(5y)35.7%

Cap/Sales(3y)6.07%

Cap/Sales(5y)4.71%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-700%

EPS Next Y-6519.8%

EPS Next 2Y-619.83%

EPS Next 3Y-49.87%

EPS Next 5Y51.91%

Revenue 1Y (TTM)66.59%

Revenue growth 3Y46.47%

Revenue growth 5Y-1.77%

Sales Q2Q%73.48%

Revenue Next Year84.81%

Revenue Next 2Y47.5%

Revenue Next 3Y43.11%

Revenue Next 5Y27.69%

EBIT growth 1Y-41.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year37.18%

EBIT Next 3Y24.82%

EBIT Next 5Y22.55%

FCF growth 1Y-63.24%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-51.31%

OCF growth 3YN/A

OCF growth 5YN/A

MDxHealth SA / MDXH.BR FAQ

Can you provide the ChartMill fundamental rating for MDxHealth SA?

ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR.

What is the valuation status for MDXH stock?

ChartMill assigns a valuation rating of 0 / 10 to MDxHealth SA (MDXH.BR). This can be considered as Overvalued.

Can you provide the profitability details for MDxHealth SA?

MDxHealth SA (MDXH.BR) has a profitability rating of 1 / 10.

What is the financial health of MDxHealth SA (MDXH.BR) stock?

The financial health rating of MDxHealth SA (MDXH.BR) is 2 / 10.

MDxHealth SA (MDXH.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MDxHealth SA / MDXH.BR FAQ

Can you provide the ChartMill fundamental rating for MDxHealth SA?

What is the valuation status for MDXH stock?

Can you provide the profitability details for MDxHealth SA?

What is the financial health of MDxHealth SA (MDXH.BR) stock?